Salicylate administered to man in sufficiently large dosage (5 to 6 or more Gm. per day) causes marked uricosuria, characterized by substantially increased urate/inulin clearance ratios attributable to inhibition of tubular reabsorption of the filtered urate. In smaller dosage (1 to 2 Gm. per day) salicylate exerts a contrary effect, retention of urate, associated with lower than normal urate/inulin clearance ratios (1-8). When small doses of salicylate are given concurrently with probenecid, the retention of urate caused by the salicylate is sufficiently pronounced to counteract, to a marked degree, the uricosuric effect of the probenecid (9, 10). Phenylbutazone and phenylbutazone metabolite I similarly cause marked retention of urate when administered in low dosage (7), and are uricosuric in large dosage.
Salicylate administered to man in sufficiently large dosage (5 to 6 or more Gm. per day) causes marked uricosuria, characterized by substantially increased urate/inulin clearance ratios attributable to inhibition of tubular reabsorption of the filtered urate. In smaller dosage (1 to 2 Gm. per day) salicylate exerts a contrary effect, retention of urate, associated with lower than normal urate/inulin clearance ratios (1) (2) (3) (4) (5) (6) (7) (8) . When small doses of salicylate are given concurrently with probenecid, the retention of urate caused by the salicylate is sufficiently pronounced to counteract, to a marked degree, the uricosuric effect of the probenecid (9, 10) . Phenylbutazone and phenylbutazone metabolite I similarly cause marked retention of urate when administered in low dosage (7) , and are uricosuric in large dosage.
Two explanations of this paradoxical effect have been offered (5, 7, 8) . It is conceivable that the tubular transport system effecting reabsorption of urate might be stimulated by small doses and suppressed by larger doses of the drugs in question. Or, a postulated tubular excretory mechanism for urate (not apparent in the usual clearance measurements in man) might be inhibited by small doses, thus causing urate retention; and when larger doses are given tubular reabsorption of urate also is suppressed, the net effect then being uricosuric.
The present study documents the paradoxical action of salicylate by providing more detailed data on the effect of small, intermediate and large doses on the 24 hour urinary urate excretion, using analytical methods incorporating precautions to obviate errors due to the presence of a salicylate metabolite, gentisic acid. The relationships between the renal excretion of salicylate and of urate are then examined by means of simultaneous clearance techniques, including studies under conditions of urine pH made to vary from markedly acid to markedly alkaline. Clearance data on the antagonistic effect of small doses of salicylate on probenecid uricosuria, and vice versa, also are presented. Finally, the implications of the results as a whole are considered in relation to current concepts of renal mechanisms for the excretion of salicylate and of urate, with special reference to inferences regarding the possibility of tubular excretion of urate in man.
METHODS
The subjects selected for investigation were all adult, gouty males, in the intercritical phase of the disorder. Forty-four studies were made in 23 of these subjects to determine the effect of orally administered acetylsalicylic acid, in divided doses totaling 1.0, 2.0, 3.0 and 5.2 Gm. per day, respectively, on the 24 hour urinary urate excretion and the serum urate level. All subjects were maintained on a constant diet low in purines and restricted in protein (60 to 75 Gm. per day) for at least three days preceding study. Twenty-four hour collections of urine were then made for eight or 12 days, blood samples being secured at appropriate intervals. After a four day control period, the patient received the prescribed daily medication for four successive days. The mean daily urinary urate output during this four day medication period, and the serum urate level on the morning of the fourth day of medication, were taken to represent the response to salicylate. Determinations were made also in the four day postmedication period in most instances. Serum and urine salicylate levels were measured in representative cases during the medication period.
Simultaneous urate, salicylate, inulin and para-aminohippurate (PAH) clearance measurements were made in 38 studies in 35 gouty subjects. Standard renal clearance techniques were employed, as previously described in detail (11) . In every experiment three premedication inulin and PAH clearance periods, each of 15 to 20 minutes' duration, were first obtained.
EFFECT OF SALICYLATE ON URATE EXCRETION IN MAN
Ten clearance studies were designed to determine the effect of slowly rising and declining plasma and urine salicylate concentrations on the urate clearance. Sodium salicylate was infused slowly at first (16 mg. per minute) for three 10 minute collection periods, then more rapidly for four to seven additional periods, each of 15 to 20 minutes' duration, until a total of 2 to 4 Gm. sodium salicylate had been delivered. Blood samples were procured at the midpoint of each urine collection period. After termination of the salicylate infusion, the collection of (spontaneous) voidings of urine was continued at two hour intervals during the day and four hour intervals during the night, over a period of 20 to 22 hours. Blood samples were taken at the beginning and end of the postinfusion period.
Two of the subjects of the preceding experiments (A. M. and M. M.) excreted a strongly acid urine and the results were included in a study of the effects of low urinary pH on salicylate uricosuria. To amplify these data two additional subjects (S. H. and M. L.) were given ammonium chloride, 16 Gm. in four divided oral doses on the day before the experiment, and 4 Gm. more one hour immediately preceding study. The protocol then followed was the same as in the previous experiments, except for omission of postinfusion urine collections.
Nine clearance studies were designed to determine the effect of alkalinization of the urine, by simultaneous injection of sodium bicarbonate, on salicylate uricosuria. Sodium salicylate was infused slowly in three instances (A. S., J. H., D. R.), as already described. In the six remaining subjects an initial priming dose of 3 Gm. sodium salicylate was given, followed by a sustaining infusion of 0.4 per cent sodium salicylate at a rate of about 4 ml. per minute for 30 to 60 minutes. Urine and blood samples were collected at appropriate intervals. Then, while the sodium salicylate infusion was continued, a priming dose of 7.5 per cent sodium bicarbonate was rapidly injected, the administration of sodium bicarbonate being sustained at a slower rate until a total of 15 Gm. had been delivered. Three or four 15 to 20 minute collection periods were obtained.
Five additional clearance studies were carried out similarly except that acetazolamide, 1.0 Gm., was substituted for sodium bicarbonate to alkalinize the urine.
To determine the effect on urate clearance of alkalinization of the urine per se, without prior administration of salicylate, three clearance studies were made with sodium bicarbonate alone, performed in the manner already described, and four with acetazolamide alone, given intravenously (two experiments) or by mouth (two experiments).
The interaction of salicylate and probenecid on urinary urate excretion was first investigated by concomitant oral administration of the drugs, then more precisely by clearance techniques. The latter experiments were initiated by establishment of premedication Curate/Cinulin ratios. In four experiments probenecid was first administered by injection of 20 mg. per Kg. body weight within 20 minutes; then a small priming dose (0.3 Gm.) of sodium salicylate was given to establish low plasma salicylate levels, followed by a sustaining solution at accelerating rate until 2.0 to 3.0 Gm. sodium salicylate was delivered over a period of approximately two hours. In four additional experiments the order of drug administration was reversed so as to investigate the effect of probenecid on salicylate uricosuria. A priming dose of 2.0 Gm. sodium salicylate was first rapidly injected; then a sustaining solution of 2.0 Gm. was given more slowly over a period of two hours. At the end of the first hour, an increase in Curate/Cinulin having already been established, probenecid, 20 mg. per Kg. body weight, was rapidly injected. Blood and urine samples were procured at appropriate intervals throughout the experiments.
The standard analytical techniques employed for inulin, PAH, urine pH and salicylate in plasma and urine have been indicated elsewhere (11) . Plasma and urine urate concentrations were determined in part spectrophotometrically (12) , in part by a modification (12) of the colorimetric method of Buchanan, Block and Christman. (13) , which incorporates uricase digestion and the use of arsenophosphotungstic acid reagent and urea cyanidecarbonate. In this latter method the "true" urate content is determined by difference, the total chromogens minus residual (nonurate) chromogens persisting after incubation of the serum or urine with uricase in borate buffer at pH 9.3. Under ordinary circumstances in both gouty and nongouty individuals, 85 to 90 per cent of the total chromogens are found by this procedure to be "true" urate, and the results check satisfactorily with spectrophotometric methods of uric acid determination (12) . However, in subjects receiving large doses of salicylate by mouth the "true" urate values thus obtained by the colorimetric method were found to be too high.
The cause of these discrepancies was investigated, incorporating an additional step into the procedure by incubating samples also in control tubes containing only borate buffer, pH 9.3, without uricase. Ordinarily, no significant difference in total chromogen results, the mean change in 13 urine samples being -0.7 per cent. However, in 12 urine samples from patients given salicylate by mouth the total chromogen content decreased 5.7 to 35.4 per cent (mean fall, 20 per cent). This finding suggested the presence in the urine of appreciable quantities of a chromogenic metabolite of salicylic acid which was unstable in alkaline solution and consequently ordinarily included in the "true" urate fraction. The metabolite in question was isolated by counter-current distribution techniques and identified as gentisic acid, which was found to give as much color with arsenophosphotungstic acid reagent as uric acid (14) . Salicylic acid and salicyluric acid are not chromogenic.
In order to estimate the magnitude of the error involved by the presence of gentisic acid, 16 normal and gouty subjects were administered 5.2 Gm. per day of acetylsalicylic acid by mouth. The mean increase in total chromogens in the 24 hour urine, as compared with the premedication excretion, was 369 mg.; of this increase approximately 50 per cent was "true" urate, 42 per cent was in the ether-soluble chromogen fraction (chiefly gentisic acid), and 8 per cent in the aqueous-solubIe nonurate chromogen fraction. In individual cases the ethersoluble chromogen constituted 9.5 to 34.4 per cent (mean, (Figure 2) , and urinary excretion of free salicylate was 0.3 to 0.6 mg. per minute. The maximum reduction in Curate/Cinuiin noted in these experiments averaged 38.5 per cent (range, 13.7 to 58.8 per cent).
As the infusion of salicylate was maintained, Curate/Cinulin returned to the control range, and continued to rise to uricosuric levels. Distinctly increased urate/inulin clearance ratios were noted after the cumulative injection of 1.5 to 3.0 Gm. sodium salicylate, with plasma salicylate levels of 10 to 12 mg. per cent or higher ( Figure  2 ), and urinary excretion of free salicylate 0.4 to 0.9 mg. per minute or more. The infusion was terminated without attempting to attain a maximal uricosuric effect.
As the plasma salicylate and urinary excretion of free salicylate levels slowly declined after discontinuance of the salicylate infusion, the same sequence of events was observed in reverse order (Figure 3) . For The data in Table IV indicate that in subjects with low urine pH a larger than customary cumulative dose of injected salicylate is required to elicit a significant rise in urinary excretion of free salicylate, 3 or 4 Gm. to achieve urinary excretion of free salicylate levels of about 0.6 mg. per minute, whereas at pH levels within the usual range such doses result in UV salicylate levels of 1 to 2 mg. per minute. The corresponding plasma salicylate levels after infusion of 3 Gm. salicylate were 18 to 32 mg. per cent as compared with 12 to 20 mg. per cent. Larger than customary cumulative doses of salicylate, from 2 to more than 4 Gm., were required also to elicit a significant rise in Curate/Cinulin above the premedication level. In the case of M. L. even 5.0 Gm. sodium salicylate failed to cause any appreciable increase in urate excretion. No concomitant rise in plasma urate was noted in most instances, presumably because of the short duration of the experiments.
In the systemic acidosis, with acid urine, produced by starvation and by high fat diets there is inhibition of urinary urate excretion (15, 16) . In three subjects of this study (not receiving salicylate) given ammonium chloride by mouth to reduce the urine pH to 4.9 to 5.1, a maximal decline of 17 to 37 per cent was noted The clearance studies summarized in Table  VII delineate these effects more precisely. In 0. G. and S. L., the initial Curate/Cinulin ratios increased five-to sevenfold after rapid infusion of probenecid, fell sharply to approximately twofold values as sodium salicylate was slowly infused, then rose again as the plasma salicylate reached levels commonly associated with salicylate uricosuria. The reverse sequence, injection of probenecid after establishment of salicylate uricosuria, caused a modest but fairly consistent decrease in the augmented excretion of urate and a slight decline in the elevated Curate/Cinulin ratios produced by salicylate. These changes were associated with a fall in urinary excretion of salicylate and rise in plasma salicylate. There was no indication of any additive effect of the two uricosuric agents. The data define three distinct facets of the action of salicylate on the renal mechanisms for excretion of urate in man. The first discernible effect of salicylate is demonstrated to be suppressive, associated with relatively low concentrations of salicylate in the plasma and urine produced by small doses, such as are commonly employed for general analgesic purposes.' Large doses (high salicylate concentrations in the plasma and urine) have a markedly augmentative effect. Betwixt these, in an intermediate zone of dosage, the net effect of salicylate is apt to be negligible; the drug seemingly is virtually inactive in respect to the urinary excretion of urate. The absolute dosage of salicylate required to initiate this sequence varies somewhat from individual to individual, the urine pH being one important variable in this regard, but the relative dosage sequence appears generally to hold in normal and gouty man.
Before understaking an analysis of this paradoxical effect, it would be useful to summarize present knowledge of the mechanisms of renal excretion of salicylate and of urate in man.
Mechanisms of renal excretion of salicylate in man
Approximately one-third of the plasma salicylate is not bound to plasma proteins in man (11) and is presumed to be filtered at the glomerulus. The subsequent fate of the filtered free salicylate is modified by the urine pH. Under the ordinary circumstances of slightly acid urine, Cfree saiicylate/Cinulin is of the order 0.2 to 0.4 (11), implying tubular reabsorption of the filtered free salicylate. Of the salicylate appearing in acid urine, only a small part (about 20 per cent or less, depending on the urine pH) is excreted as free salicylate. The major proportion is in conjugated form (18) , combined with glycine as salicyluric acid (55 to 65 per cent) and with glucuronic acid as salicyl acyl and phenolic glucuronides (20 to 30 per cent) (18, 19) . Approximately 20 per cent of ingested salicylate IAs mentioned elsewhere (12) , the hyperuricemia thus resulting from ingestion of salicylate in low dosage is not uncommonly encountered and is frequently misconstrued; when associated with joint pains it is sometimes attributed to gout. Even formal studies of the interpretation of hyperturicemia may neglect this iatrogenic etiology (17) . cannot be recovered in the urine as salicyl compounds because of metabolic conversion to gentisic acid and other degradation products (18) .
If the urine is made distinctly alkaline, whether by administration of sodium bicarbonate (11, (19) (20) (21) (22) (23) (24) (25) or acetazolamide (25) , or as a result of overbreathing (25) , the rate of urinary excretion of salicylate is greatly enhanced, and the proportion of free salicylate increases to 60 to 90 per cent or more of the total urinary salicylate. This marked rise in Cfree salicylate is not due to any increase in the filtered load of free salicylate, and hence is ascribable to diminution of tubular reabsorption. Cfree salicylate/Cinulin may exceed 1.0 if the urine is made sufficiently alkaline, indicating tubular excretion of free salicylate in man (11, 19, 23, 25) .
In view of the strikinig urinary pH dependence of the renial excretioni of salicylic acid (pKa about 3.0), "passive" tubular transfer processes, depeindenit uponl the pH gradient between the tubular urine anid the peritubular fiuid, may be assumed to play an important role in both tubular reabsorption and excretion of free salicylate (25) (26) (27) . However, tubular transfer of free salicylate is not altogether attributable to nonionic diffusion, since probenecid causes a substantial reduction in urinary excretion of free salicylate with a corresponding rise in plasma salicylate, irrespective of the urine pH (11, 19) . This effect of probenecid is reminiscent of its action on the renial excretion of penicillini and other compounds "actively" secreted by the tubules. "Active" tubular secretion of free salicylate is further implied by transfer against an H+ gradient, as indicated by its (limited) reabsorption in alkaline urine and suspected excretion in acid urine (11, 19, 23) . Tubular secretion of salicyluric acid (28) and of salicyl acyl and phenolic glucuronides (19) has been clearly demonstrated by Schachter and Manis (19) , and occurs at a rate independent of the urine pH, but determined chiefly by the rate of conjugation, largely in the liver (19 (31, 32) , indicates tubular reabsorption. The tubular capacity for reabsorption of urate has been shown to be limited, of the order of 15 mg. per minute in normal manl (31) , but nevertheless much larger than the urate load delivered to the tubules in normal and most gouty subjects under ordinary circumstances (31, 32) .
The conventionial interpretationi of urate clearanice data in man limits the role of the kidniey to glomerular filtration and tubular reabsorption of urate. The urate appearinig in the urinie is considered to represent that 5 to 10 per cent of the filtered urate load which has escaped reabsorption ( Figure 4 ). Another possible interpretation, also consistent with the clearance data, considers tubular reabsorption of the filtered urate to be virtually complete under ordinary circumstances, and the urinary urate to be derived by tubular excretion (7, 32, 33) (Figure 4) , i.e., a mechainism similar to that postulated for potassium (34, 35) fate (36) . The processes of tubular reabsorption and excretion of urate both are conceived to be chiefly "active," in view of their limited capacity and the inhibiting effects of a variety of chemical agents. Nonionic diffusion of uric acid (pKa 5.4) appears to play a minor role in tubular tranisfer. While the excretioni of urate is diminiished in acid urinie anid slightly increased in urine made alkaline by the administration of sodium bicarbonate, alkalinizationi of the urine by use of acetazolamide leads to some decrease in renal excretion of urate (37) . The contrary effects of alkalinizationi of the urine with bicarbonate and acetazolamide indicate that, in contrast to the nionionic diffusion of other weak acids (27) , the tubular transfer of urate is not greatly influeniced by alkalinie urinie pH alone.
Relationship of concentration of free salicylatej in the tubular urine to the tubular regulation of urate excretion To return now, in the light of the foregoinlg resume, to the primary consideration of this study, a critical point in interpretation of the paradoxical effects of low, intermediate and high dosages of salicylate is whether they are related to the corresponding salicylate concentrations in the plasma or in the tubular urine. This would be difficult to establish under ordinary circumstances, in which the rate of renal excretion of salicylate parallels the plasma salicylate concentrationi. However, dissociation of this relationship can be effected by renderinig the urine distinctly acid or alkaline. In distinctly acid urinie, urinary excretion of free salicylate remainis lower than ordinarily, eveni after relatively large doses of salicylate, anid the plasma salicylate rises iniordinately. Under with bicarbonate without prior administration of salicylate. When acetazolamide is used to alkalinize the urine in patients receiving salicylate, the excretion of free salicylate again is accelerated, and the plasma salicylate falls unless constantly replenished. However, Curate/Cinulin is not increased in this instance, but declines somewhat below the levels reached by acetazolamide without prior administration of salicylate.
The combined results of experiments using ammonium chloride, sodium bicarbonate or acetazolamide indicate that salicylate exerts its various effects on urate excretion largely at the renal tubular level, although these effects seem to be modified by the state of metabolic acidosis or alkalosis. Further, the paradoxical effects of salicylate in varying dosage appear to be chiefly related to the correspondingly varied concentrations of free salicylate in the tubular urine (8) . This relationship, illustrated in Figure 5 , is represented by a discontinuous curve. Low ranges of urinary excretion of free salicylate are associated with decreased Curate/Cinulin ratios, which at first decline further as urinary excretion of free salicylate slowly, increases. The point of minimum inflection is formed by the intersection with another, sharply rising curve which represents increasing Curate/Cinulin ratios, to markedly uricosuric levels, as urinary excretion of free salicylate further increases. The inexplicable apparent loss of drug potency at intermediate dosage levels clearly is the resultant of opposing suppressive and augmentative forces, in such relative proportions as virtually to nullify each other, and thus yield an insignificant net effect.
These results can be reconciled with the conventional concept of renal regulation of urate excretion only with some difficulty. The uricosuric effect of large doses of salicylate, associated with markedly increased urate/inulin clearance ratios, is readily understandable as due to inhibition of tubular reabsorption of urate, as in the case of other potent uricosuric agents (38) (39) (40) (41) (42) . The suppressive effect of small doses of salicylate, however, requires the rather awkward assumption of stimulation of tubular reabsorption of urate by the same drug, and without any change in filtered urate load. A similar explanation presumably would apply to urate retention caused by phenylbutazone in low dosage (7) and by pyrazinamide (43) and lactate (44) . The apparent impotency of intermediate doses of salicylate poses a dilemma. The single tubular transport system for urate would seem to be simultaneously stimulated and suppressed by the same drug in the same dosage.
The alternative concept of renal regulation of urate excretion, which postulates a tubular excretory as well as reabsorptive transport mechanism, supposes the suppressive effect of small doses of salicylate (and other agents with like action) to be due to inhibition of tubular secretion of urate (7, 8, 32, 33) .2 When the concentration of free salicylate in the tubular urine is sufficiently increased, it is assumed that inhibition of the reabsorptive mechanism also occurs. In the intermediate range of urinary excretion free salicylate, inhibition of urate secretion is marked whereas inhibition of urate reabsorption is so slight that the net effect is virtually to cancel out the effect of either action alone, the net result on the ex-cretion of urate being negligible. High concentrations of free salicylate in the tubular urine are considered markedly to inhibit both tubular reabsorption and secretion of urate (7, 8, 32, 33) . The net effect of such marked dual inhibition would be expected to be uricosuric, since the quantity of urate normally reabsorbed from the glomerular filtrate in man is 10 to 20 or more times greater than the quantity eliminated in the urine.
The nature of the inhibition of the reabsorptive (and secretory) processes of tubular transfer of urate, by salicylate and the other drugs in question, must remain a matter of speculation for the present. Competition for some common component of the reabsorptive and secretory tubular transfer mechanisms may occur.
The interacting influences of salicylate and probenecid, when jointly administered, on the tubular regulation of urate excretion The inhibition of probenecid uricosuria by small doses of salicylate poses a further dilemma for the conventional concept of the renal regulation of urate excretion, since here again there would seem to be simultaneous inhibition and stimulation of a single tubular transfer system, in this instance by two different drugs. A similar difficulty arises in connection with the inhibition of probenecid uricosuria by other drugs which, when given alone, cause marked retention of urate (for example, lactate) (44).
The explanation alternatively offered postulates that the inhibition of tubular reabsorption of urate produced by probenecid is partially counterbalanced by simultaneous inhibition of tubular secretion of urate by salicylate in low dosage (33) . A similar dual mechanism is presumed to underlie the inhibitory effect of small doses of salicylate on the enhanced urate excretion produced by other potent uricosuric agents, such as zoxazolamine (42) and the phenylbutazone analogs, G-25671 and G-28315 (45, 46) . It is interesting to note that salicylate, which has no effect on tubular secretion of penicillin, in no way influences the inhibition of penicillin secretion by probenecid (47) .
It should be pointed out, however, that the observed counterbalance of probenecid uricosuria by small doses of salicylate is greater than anticipated by the postulated inhibition of tubular secretion of urate, since the quantity of urate secreted apparently is small in relation to that reabsorbed. Other factors, as yet obscure, must therefore be presumed also to be operative. Another discrepancy is the failure to observe an additive effect if salicylate in large (uricosuric) dosage is given when probenecid uricosuria is already produced, or if probenecid is administered when salicylate uricosuria already obtains (9, 48, 49) . Such an additive effect is in fact noted when zoxazolamine and G-28315 are administered jointly, or with probenecid (42, 50) .3 However, in the case of salicylate uricosuria, probenecid exerts a moderate depressant effect, associated with a decline in the free salicylate concentration in the tubular urine. This response seems to be related to the inhibitory effect, already referred to (11, 19) 
